Immunological biomarkers improve the accuracy of clinical risk models of infection in the acute phase of ischemic stroke

Cerebrovascular Diseases

Volumn 35, Issue 3, 2013, Pages 220-227

  Salat, David ^a,b   Penalba, Anna ^a   García Berrocoso, Teresa ^a   Campos Martorell, Mireia ^a   Flores, Alan ^a,b   Pagola, Jorge ^b   Bustamante, Alejandro ^a   Quintana, Manuel ^b   Giralt, Dolors ^a   Molina, Carlos ^b   Alvarez Sabín, José ^b   Montaner, Joan ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acute cerebral infarction; Infection; Outcome research; Th1 Th2 profile

Indexed keywords

ACUTE PHASE PROTEIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CHOLECYSTITIS; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FUNCTIONAL STATUS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INFECTION RISK; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; SMOKING; STROKE PATIENT; TH1 TH2 BALANCE; URINARY TRACT INFECTION; VALVULAR HEART DISEASE;

EID: 84874631229     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000346591     Document Type: Article

References (42)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics: 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 1193:e21-e181
2. Kim AS, Johnston SC: Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011; 124: 314-323
3. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, et al; on behalf of the Berlin Stroke Register investigators: Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011; 77: 965-972
4. Bravata DM, Wells CK, Lo AC, Nadeau SE, Melillo J, Chodkowski D, et al: Processes of care associated with acute stroke outcomes. Arch Intern Med 2010; 170: 804-810
5. Vermeij FH, Scholte op Reimer WJ, de Man P, de Man P, van Oostenbrugge RJ, Franke CL, et al; on behalf of the Netherlands Stroke Survey Investigators: Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 2009; 27: 465-471
6. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D: Post-stroke infection: A systematic review and meta-analysis. BMC Neurol 2011; 11: 110
7. Wartenberg KE, Stoll A, Funk A, Meyer A, Schmidt JM, Berrouschot J: Infection after acute ischemic stroke: risk factors, biomarkers, and outcome. Stroke Res Treat 2011; 2011: 830614
8. Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Molina CA, et al: Simvastatin in the acute phase of ischemic stroke: A safety and efficacy pilot trial. Eur J Neurol 2008; 15: 82-90
9. Muraille E, Leo O: Revisiting the Th1/Th2 paradigm. Scand J Immunol 1998; 47: 1-9
10. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al: Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25: 2220-2226
11. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526
12. Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
13. Horan TC, Andrus M, Dudeck MA: DC/ NHSN surveillance definition of health careassociated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332
14. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054
15. Pencina MJ, D'Agostino RB, Vasan RS: Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48: 1703-1711
16. Ros L, Garcia M, Prat J, Gonzalez C, Gimeno C, Albert A, Pascual JM: Predictors of nosocomial infection in acute stroke. Relation with morbimortality and outcome. Med Clin (Barcelona) 2007; 128: 441-447
17. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V: Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci 2001; 22: 289-296
18. Shenhar-Tsarfaty S, Assayag EB, Bova I, Shopin L, Berliner S, Shapira I, Bornstein NM: Early signaling of inflammation in acute ischemic stroke: clinical and rheological implications. Thromb Res 2008; 122: 167-173
19. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn A, et al: The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 2010; 30: 85-92
20. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, et al: Blood biomarkers for the diagnosis of acute cerebrovascular diseases: A prospective cohort study. Cerebrovasc Dis 2011; 32: 141-147
21. Jickling GC, Sharp FR: Blood biomarkers of ischemic stroke. Neurotherapeutics 2011; 8: 349-360
22. Garcia-Berrocoso T, Fernandez-Cadenas I, Delgado P, Rosell A, Montaner J: Blood biomarkers in cardioembolic stroke. Curr Cardiol Rev 2010; 6: 194-201
23. Worthmann H, Tryc AB, Goldbecker A, Ma YT, Tountopoulou A, Hahn A, et al: The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 2010; 30: 85-92
24. Ahmad O, Wardlaw J, Whiteley WN: Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: A systematic review. Cerebrovasc Dis 2012; 33: 47-54
25. Herzum I, Renz H: Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008; 15: 581-587
26. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al: Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-344
27. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, Torres F, et al: Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry 2006; 77: 1279-1281
28. Klehmet J, Harms H, Richter M, Prass K, Volk HD, Dirnagl U, et al: Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 2009; 158: 1184-1193
29. Fluri F, Morgenthaler NG, Mueller B, Christ-Crain M, Katan M: Copeptin, procalcitonin and routine inflammatory markers-predictors of infection after stroke. PLoS One 2012; 7:e48309
30. Montaner J, Fernandez-Cadenas I, Molina CA, Ribo M, Huertas R, Rosell A, et al: Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006; 37: 1205-1210
31. Newcomb DC, Boswell MG, Huckabee MM, Goleniewska K, Dulek DE, Reiss S, et al: IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner. J Immunol 2012; 188: 1027-1035
32. Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM, Foster PS: Interleukin-13.promotes susceptibility to chlamydial infection of the respiratory and genital tracts. PLoS Pathog 2011; 7:e1001339
33. Sacco S, Toni D, Bignamini AA, Zaninelli A, Gensini GF, Carolei A; on behalf of the SIRIO Study Group: Effect of prior medical treatments on ischemic stroke severity and outcome. Funct Neurol 2011; 26: 133-139
34. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, et al: Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009; 20: 50-57
35. Scheitz JF, Endres M, Heuschmann PU, Audebert HJ, Nolte CH: Reduced risk of poststroke pneumonia in thrombolyzed stroke patients with continued statin treatment. Int J Stroke 2012, doi: 10.1111/j.1747-4949.2012.00864.x
36. Meisel A, Meisel C, Harms H, Hartmann O, Ulm L: Predicting post-stroke infections and outcome with blood-based immune and stress markers. Cerebrovasc Dis 2012; 33: 580-588
37. Schuetz P, Albrich W, Mueller B: Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011; 9: 107
38. McColl BW, Allan SM, Rothwell NJ: Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009; 158: 1049-1061
39. Schwarz S, Al-Shajlawi F, Sick C, Meairs S, Hennerici MG: Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after severe acute ischemic stroke: the Mannheim infection in stroke study (MISS). Stroke 2008; 39: 1220-1227
40. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F, et al: The Early Systemic Prophylaxis of Infection after Stroke study: A randomized clinical trial. Stroke 2005; 36: 1495-1500
41. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, et al: Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial. PLoS One 2008; 3:e2158
42. Salat D, Delgado P, Alonso S, Ribo M, Santamarina E, Quintana M, et al: Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients. Eur Neurol 2011; 65: 82-87.